Aligos Therapeutics, Inc. (ALGS) Stock

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is led by CEO Lawrence Blatt, publicly traded since 2020.

Aligos Therapeutics, Inc. (ALGS) stock trades at $4.78 with a market capitalization of $29.85M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.76, reflecting a net loss over the last twelve months, price-to-book of 1.81, price-to-sales of 1.09. Over the past 52 weeks the stock has ranged between $3.98 and $13.69, and currently trades 65.1% below its 52-week high.

On profitability, Aligos Therapeutics, Inc. generates a return on equity (ROE) of -160.72% (negative, reflecting a net loss), return on capital employed of -207.97%, an operating margin of -4400.00%, a net profit margin of -241.01%.

Aligos Therapeutics, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Aligos Therapeutics, Inc. reported revenue of $0 rising to $2.0M. Compounded, revenue has grown —% a year over five years, -47.7% over three, -50.0% over the last twelve months. Net profit fell to $-24.0M.

The most recent net margin is -241.01%. On a trailing twelve-month basis to Jun '26, revenue is $32.0M and net profit $-77.0M.

Borrowings fell from $14.0M to $5.0M, cash from operations was $-83.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged 30.0% over five years, and was -44.4% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Aligos Therapeutics, Inc. (ALGS) — frequently asked questions